Top Page
Dr. Martens Plc
(LSE:DOCS)
Dr. Martens Plc (DOCS) vs. iShares MSCI United Kingdom ETF (EWC)
Dr. Martens Plc Business Overview & Revenue Model
Dr. Martens Plc Earnings Call Summary
Dr. Martens Plc Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.00M | 787.60M | 877.10M | 1.00B | 908.30M | 773.00M |
| Gross Profit | 479.70M | 511.70M | 575.20M | 618.10M | 578.80M | 470.50M |
| EBITDA | 152.70M | 110.50M | 196.30M | 235.00M | 265.10M | 143.30M |
| Net Income | 15.30M | 4.50M | 69.20M | 128.90M | 181.20M | 34.70M |
Balance Sheet | ||||||
| Total Assets | 865.40M | 889.80M | 952.40M | 992.60M | 859.10M | 652.80M |
| Cash, Cash Equivalents and Short-Term Investments | 95.70M | 155.90M | 111.10M | 157.50M | 228.00M | 113.60M |
| Total Debt | 397.10M | 404.10M | 477.00M | 451.80M | 393.80M | 366.40M |
| Total Liabilities | 536.30M | 523.40M | 584.20M | 588.40M | 530.90M | 502.10M |
| Stockholders Equity | 329.10M | 366.40M | 368.20M | 404.20M | 328.20M | 150.70M |
Cash Flow | ||||||
| Free Cash Flow | 118.00M | 177.60M | 139.50M | 25.90M | 159.40M | 99.50M |
| Operating Cash Flow | 126.40M | 196.30M | 167.90M | 77.30M | 184.40M | 121.40M |
| Investing Cash Flow | -14.00M | -15.30M | -25.50M | -50.60M | -25.00M | -21.90M |
| Financing Cash Flow | -110.50M | -134.20M | -185.90M | -99.50M | -47.00M | -44.00M |
Dr. Martens Plc Technical Analysis
Dr. Martens Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £14.81B | 9.50 | 51.86% | 1.80% | 9.74% | 0.92% | |
71 Outperform | £3.58B | 26.72 | 19.64% | 1.21% | 14.60% | 58.84% | |
64 Neutral | £604.61M | -23.98 | 4.61% | 3.36% | -2.59% | -46.13% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
55 Neutral | £3.69B | -40.23 | -2.99% | ― | -9.44% | -170.53% | |
54 Neutral | £21.96M | 17.87 | 8.50% | ― | -6.24% | -82.21% | |
52 Neutral | £277.70M | -1.12 | -111.93% | ― | -14.89% | 12.08% |
Dr. Martens Plc Corporate Events
Dr. Martens plc has disclosed share transactions by its chief executive officer, Ije Nwokorie, and chief financial officer, Giles Wilson, under the company’s HMRC-approved all-employee Share Incentive Plan. The plan allows staff to buy partnership shares from salary and receive matching shares on a one-for-one basis, supporting broader employee equity participation.
On 11 March 2026, both executives purchased 236 partnership shares each at 63.50 pence per share and were granted 236 matching shares each at no cost. The disclosure, made under UK Market Abuse Regulation requirements, modestly increases senior management’s equity exposure and signals continued alignment of leadership incentives with shareholder interests.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £63.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has confirmed that its issued ordinary share capital stands at 967,343,738 shares, each carrying one voting right, with no shares held in treasury. This figure represents the total number of voting shares in the company and serves as the key reference point for investors assessing whether they must disclose holdings or changes in their stake under UK transparency rules.
The updated share count clarifies the company’s capital structure and supports regulatory compliance for significant shareholders under the Financial Conduct Authority’s disclosure regime. By confirming that all issued shares carry voting rights, Dr. Martens provides greater transparency for market participants tracking ownership thresholds, which can influence governance dynamics and investor relations in the FTSE 250 group.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £73.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens has reported share dealings by senior management under its HMRC-approved Share Incentive Plan, an all-employee scheme that allows staff to buy partnership shares from salary and receive matching shares from the company. The plan is designed to align employees’ and executives’ interests with shareholders by increasing equity participation across the workforce.
On 11 February 2026, chief executive officer Ije Nwokorie and chief financial officer Giles Wilson each purchased 219 partnership shares at 68.75 pence and were granted 219 matching shares at no cost. The transactions, partly executed on the London Stock Exchange and partly off-market, signal ongoing executive commitment to the business and comply with disclosure requirements under the UK Market Abuse Regulation.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £73.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has confirmed that, as of 30 January 2026, its issued ordinary share capital stands at 967,319,559 shares, each carrying one voting right, with no shares held in treasury. This updated total voting rights figure provides the formal denominator that investors must use when calculating whether they need to disclose new or changed holdings under UK transparency rules, clarifying the company’s current equity base for shareholders and market participants.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £72.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has instructed the trustee of its Employee Benefit Trust to purchase up to 10 million of the company’s ordinary shares on the open market, to be held on an unallocated basis for use in meeting current and future obligations under its employee share plans. The move underlines the group’s ongoing commitment to equity-based remuneration and could modestly tighten the available free float, while providing flexibility in incentivising staff across its global operations without immediately issuing new shares.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens reported a modest decline in third-quarter group revenue as it pushed ahead with a “consumer-first” turnaround that prioritises full-price sales over discounting, particularly in ecommerce. For the 13 weeks to 28 December 2025, revenue fell 2.7% at constant currency to £253m, with direct-to-consumer sales down 6.5% and wholesale up 9.5%, reflecting a deliberate pullback from clearance activity and a tougher consumer backdrop, especially in EMEA where DTC revenue slumped 12% while wholesale grew 13%. The Americas delivered 2% revenue growth, driven by stronger retail and a more disciplined wholesale mix, and APAC saw a small overall decline as reduced promotions hit DTC but boosted full-price performance, with South Korea continuing to grow strongly. Management said it is on track to deliver all four strategic objectives for FY26, including reducing reliance on discounted wholesale in the US, expanding newer product families, opening new markets via capital-light partnerships—such as an expanded Latin American distribution deal—and simplifying its operating model to be closer to local consumers. Despite expecting broadly flat constant-currency revenue for FY26 as it prioritises profitability and revenue quality, Dr. Martens reiterated guidance for significant year-on-year growth in profit before tax, though it warned that foreign exchange volatility now implies a larger revenue headwind and a broadly neutral effect on adjusted PBT.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens has disclosed that chief executive officer Ije Nwokorie and chief financial officer Giles Wilson have each acquired 192 ordinary shares in the company through the firm’s HMRC-approved all-employee Share Incentive Plan, at a price of 77.894 pence per share. Under the same plan, both executives were also granted 192 matching shares for no consideration, underscoring ongoing senior management participation in the company’s equity-based remuneration scheme and aligning leadership incentives more closely with shareholder interests.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £100.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has confirmed that, as of 31 December 2025, its issued ordinary share capital comprises 967,295,505 shares of GBP 0.01 each, all of which carry one voting right and none of which are held in treasury. This disclosure formalises the total number of voting shares in issue, providing investors with the denominator needed to assess and report significant shareholdings under UK transparency rules, and thereby supports regulatory compliance and clearer visibility over the company’s ownership structure.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.